Effect of the renin-angiotensin system on the vessel wall: Using ACE inhibition to improve endothelial function

Journal of Human Hypertension

Volumn 18, Issue 9, 2004, Pages 599-606

  Neutel, J M ^a  

^a Orange County Heart Institute and Research Center   (United States)

Author keywords

Angiotensin converting enzyme inhibition; Atherosclerosis; Endothelium; Renin angiotensin; Trough:peak ratio

Indexed keywords

ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BRADYKININ; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; NEUROHORMONE; PERINDOPRIL; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTERY COMPLIANCE; ATHEROSCLEROSIS; BLOOD PRESSURE; BLOOD VESSEL FUNCTION; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CORRELATION FUNCTION; COUGHING; DRUG HALF LIFE; ELECTROCARDIOGRAM; ENVIRONMENTAL FACTOR; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INCIDENCE; NONHUMAN; PATIENT CARE; PLASMA RENIN ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR ENDOTHELIUM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD VESSELS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM;

EID: 4544358748     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001714     Document Type: Review

References (47)

1. American Heart Association. Heart and Stroke Facts Statistical Update. American Heart Association: Dallas, TX, 2002.
2. McMahon S et al. Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution. Lancet 1990; 335: 765-774.
3. Grimm RH, et al, for the MIDAS Research Group. A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis: the multicenter isradipine diuretic atherosclerosis study (MIDAS). Drugs 1990; 4 (Suppl 2): 38-43.
4. Havlik RJ et al. Antihypertensive drug therapy and survival by treatment status in a national survey. Hypertension 1989; 1 (Suppl I): I-28-I-32.
5. Kannel WB. Blood pressure as a cardiovascular risk factor. Prevention and treatment. JAMA 1996; 275: 1571-1576.
6. Celentano A et al. Blood pressure and cardiac morphology in young children of hypertensive subjects. J Hypertens 1988; 6 (Suppl 4): S107-S109.
7. Dzau VJ. Atherosclerosis and hypertension: mechanisms and interrelationships. J Cardiovasc Pharmacol 1990; 15 (Suppl 5): S59-S64.
8. Dzau VJ. Tissue renin-angiotensin system: physiologic and pharmacologic implications. Circulation 1988; 77: I1-I3.
9. Glasser SP, Selwyn AP, Ganz P. Atherosclerosis: risk factors and the vascular endothelium. Am Heart J 1996; 131: 379-384.
10. Neutel JM et al. Heredity and hypertension: impact on metabolic characteristics. Am Heart J 1992; 124: 435-440.
11. Gibbons GH. Endothelial function as a determinant of vascular function and structure: a new therapeutic target. Am J Cardiol 1997; 79 (Suppl 5A): 3-8.
12. Neutel JM, Smith DHG, Graettinger WF, Weber MA. Dependency of arterial compliance on circulating neuroendocrine and metabolic factors in normal subjects. Am J Cardiol 1992; 69: 1340-1344.
13. Neutel JM. Why lowering blood pressure is not enough. The hypertension syndrome and the clinical context of cardiovascular risk reduction. Heart Dis 2000; 2: 370-374.
14. Lonn EM et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90: 2056-2069.
15. Brunner HR et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972; 286: 441-449.
16. Alderman MH et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324: 1098-1104.
17. Laragh J. Review course. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 2001; 41: 84-89.
18. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047-1052.
19. Gibbons GH. Endothelial function as a determinant of vascular function and structure: a new therapeutic target. Am J Cardiol 1997; 79: 3-8.
20. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993; 153: 937-942.
21. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
22. Nickenig G et al. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997; 95: 473-478.
23. 1 receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits. Hypertension 1999; 34 (Part 2): 969-997.
24. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994; 330: 1431-1438.
25. Cohn JN et al. Noninvasive pulse wave analysis for the early detection of vascular disease. Hypertension 1995; 26: 503-508.
26. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000; 105: 1605-1612.
27. Baron AD. The coupling of glucose metabolism and perfusion in human skeletal muscle. The potential role of endothelium-derived nitric oxide. Diabetes 1996; 45 (Suppl 1): S105-S109.
28. Baron AD. Vascular reactivity. Am J Cardiol 1999; 84: 25J-27J.
29. Baron AD. Insulin and the vasculature - old actors, new roles. J Invest Med 1996; 44: 406-412.
30. Weber MA, Smith DHG, Neutel JM, Graettinger WF. Arterial properties of early hypertension. J Hum Hyper tens 1991; 5: 417-423.
31. Clozel J-P, Kuhn H, Hefti F. Decreases of vascular hypertrophy in four different types of arteries in spontaneously hypertensive rats. Am J Med 1989; 87 (Suppl 6B): 92S-95S.
32. Asmar RG et al. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation 1988; 78: 941-950.
33. Sihm I et al. Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE-inhibitor perindopril. Blood Press 1995; 4: 241-248.
34. Thybo NK et al. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995; 25 (Part I): 474-481.
35. Weber MA. The angiotensin II receptor blockers: opportunities across the spectrum of cardiovascular disease. Rev Cardiovasc Med 2002; 3: 183-191.
36. White WB, Dey HM, Schulman P. Assessment of the daily blood pressure load as a determinant of cardiac function in patients with mild-to-moderate hypertension. Am Heart J 1989; 118: 782-795.
37. Frattola A et al. Prognostic value of 24-hour blood pressure variability. J Hypertens 1993; 11: 1133-1137.
38. Deedwania PC, Nelson JR. Pathophysiology of silent myocardial ischemia during daily life. Hemodynamic evaluation by simultaneous electrocardiographic and blood pressure monitoring. Circulation 1990; 82: 1296-1304.
39. Muller JE et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985; 313: 1315-1322.
40. White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy 1998; 18: 588-599.
41. Monopril® (product information). Bristol-Myers Squibb. Physician's Desk Reference®, Available at: www.pdrel.com/pdr/static.htm?path=pdrel/pdr/10451000.htm. Accessed on 29 August 2002.
42. Lotensin® (product information). Novartis Pharmaceuticals Corporation. Physician's Desk Reference®, 58th edn. Thomson PDR: Montvale,NJ, 2004, pp. 2279-2284.
43. Aceon® (product information). Solvay Pharmaceuticals, Inc. Physician's Desk Reference®, 58th edn. Thomson PDR: Montvale, NJ. 2004, pp. 3163-3165.
44. Accupril® (product information). Parke-Davis, A Division of Warner-Lambert Company LLC, A Pfizer Company. Physician's Desk Reference, 58th edn. Thomson PDR: Montvale, NJ, 2004, pp. 2516-2519.
45. Altace® (product information). Monarch Pharmaceuticals a wholly owned subsidiary of King Pharmaceuticals, Inc. Physician's Desk Reference®, 58th edn. Thomson PDR: Montvale, NJ, 2004, pp. 2142-2145.
46. Mavik® (product information). Abbott Laboratories. Physician's Desk Reference®, 58th edn. Thomson PDR: Montvale, NJ, 2004, pp. 489-491.
47. Meredith PA, Elliott HL. Concentration-effect relationships and implications for trough-to-peak ratio. Am J Hypertens 1996; 9: 66S-70S.